Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBONASDAQ:PTGXNASDAQ:RARENASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBOAlbireo Pharma$44.15$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsPTGXProtagonist Therapeutics$56.37+0.1%$46.72$30.67▼$60.60$3.49B2.25896,197 shs985,411 shsRAREUltragenyx Pharmaceutical$37.49-4.6%$36.04$29.59▼$60.37$3.54B0.25841,606 shs1.09 million shsVKTXViking Therapeutics$26.08-8.7%$26.46$18.92▼$81.73$2.93B0.654.06 million shs6.08 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%PTGXProtagonist Therapeutics0.00%+3.66%+26.93%+2.90%+65.94%RAREUltragenyx Pharmaceutical0.00%+0.86%+7.61%-4.70%-16.02%VKTXViking Therapeutics0.00%-6.29%-4.82%-15.57%-50.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBOAlbireo PharmaN/AN/AN/AN/AN/AN/AN/AN/APTGXProtagonist Therapeutics1.9881 of 5 stars2.52.00.00.02.12.51.3RAREUltragenyx Pharmaceutical4.4118 of 5 stars3.53.00.03.83.92.50.6VKTXViking Therapeutics4.3971 of 5 stars4.51.00.04.72.23.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBOAlbireo Pharma 0.00N/AN/AN/APTGXProtagonist Therapeutics 3.00Buy$65.4416.10% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$88.77136.78% UpsideVKTXViking Therapeutics 3.00Buy$87.15234.18% UpsideCurrent Analyst Ratings BreakdownLatest ALBO, RARE, PTGX, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.005/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.005/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/9/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBOAlbireo Pharma$40.58M22.52N/AN/A$9.11 per share4.85PTGXProtagonist Therapeutics$207.80M16.81N/AN/A$5.84 per share9.65RAREUltragenyx Pharmaceutical$590.69M6.00N/AN/A$2.76 per share13.58VKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBOAlbireo Pharma-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/APTGXProtagonist Therapeutics-$78.96M$0.7521.19N/AN/A52.76%34.68%30.98%8/5/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-101.60%-193.80%-38.15%7/30/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)Latest ALBO, RARE, PTGX, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBOAlbireo PharmaN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBOAlbireo PharmaN/A6.326.23PTGXProtagonist TherapeuticsN/A10.6910.70RAREUltragenyx PharmaceuticalN/A2.372.65VKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBOAlbireo Pharma94.25%PTGXProtagonist Therapeutics98.63%RAREUltragenyx Pharmaceutical97.67%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipALBOAlbireo Pharma6.90%PTGXProtagonist Therapeutics4.90%RAREUltragenyx Pharmaceutical5.50%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBOAlbireo Pharma13020.70 million19.27 millionOptionablePTGXProtagonist Therapeutics12061.98 million56.38 millionOptionableRAREUltragenyx Pharmaceutical1,31094.54 million86.99 millionOptionableVKTXViking Therapeutics20112.31 million106.20 millionOptionableALBO, RARE, PTGX, and VKTX HeadlinesRecent News About These CompaniesViking Therapeutics (NASDAQ:VKTX) Shares Down 5.7% - Should You Sell?June 13 at 1:55 PM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Lifted by Compagnie Lombard Odier SCmAJune 13 at 5:54 AM | marketbeat.comViking Therapeutics (VKTX) Rises on Expected DevelopmentsJune 12 at 8:30 PM | insidermonkey.comViking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to NoteJune 12 at 6:46 PM | zacks.comWe're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash WiselyJune 12 at 8:46 AM | finance.yahoo.comHarbor Capital Advisors Inc. Sells 14,094 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)June 12 at 4:51 AM | marketbeat.comViking Therapeutics Target of Unusually High Options Trading (NASDAQ:VKTX)June 12 at 2:42 AM | americanbankingnews.comBrokers Issue Forecasts for VKTX FY2026 EarningsJune 12 at 1:45 AM | americanbankingnews.comAnalysts Issue Forecasts for VKTX FY2026 EarningsJune 11, 2025 | marketbeat.comWesbanco Bank Inc. Purchases 12,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)June 11, 2025 | marketbeat.comViking Therapeutics Target of Unusually Large Options Trading (NASDAQ:VKTX)June 10, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 7.1% - Still a Buy?June 10, 2025 | marketbeat.comWas Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)?June 9, 2025 | msn.comViking Therapeutics, Inc. (NASDAQ:VKTX) Receives $87.15 Average Price Target from BrokeragesJune 9, 2025 | americanbankingnews.com1 Stock Down 34% This Year to Buy and HoldJune 8, 2025 | fool.com39,652 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by RFG Advisory LLCJune 6, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by AnalystsJune 6, 2025 | marketbeat.comProfit Investment Management LLC Buys 44,055 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)June 2, 2025 | marketbeat.comDeutsche Bank AG Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)June 2, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires New Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 31, 2025 | marketbeat.comPKO Investment Management Joint Stock Co Purchases Shares of 15,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)May 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsTesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBy Sam Quirke | June 11, 2025View Tesla Stock: Why These 2 Downgrades Are Actually a Buy SignalALBO, RARE, PTGX, and VKTX Company DescriptionsAlbireo Pharma NASDAQ:ALBOAlbireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.Protagonist Therapeutics NASDAQ:PTGX$56.37 +0.05 (+0.09%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$56.40 +0.03 (+0.04%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Ultragenyx Pharmaceutical NASDAQ:RARE$37.49 -1.80 (-4.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$37.50 +0.01 (+0.03%) As of 06/13/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Viking Therapeutics NASDAQ:VKTX$26.08 -2.50 (-8.75%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$26.22 +0.14 (+0.54%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
